# US 2026/0083747 A1 · Compositions and methods for supporting mitochondrial health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083747 A1
- Document ID: US20260083747A1
- Status: Published application
- Kind: A1
- Application number: 18/931,346
- Filed: 2024-10-30
- Published: 2026-03-26
- Earliest claimed: 2024-09-24
- Inventors: Darren LOPEZ; Dan SCHMIDT
- Web page: https://patentgrep.com/patent/US20260083747A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methylthioninium salt-containing compositions can include a methylthioninium salt and a second mitochondria-enhancing compound selected from urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4, pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1, or a combination thereof.

## Claims

### Claim 1

A methylthioninium salt-containing composition, comprising an oral dosage form of a methylthioninium salt and a second mitochondria-enhancing compound selected from:
urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4;
pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 about 50:1;
tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1;
or a combination thereof.

### Claim 2 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein:
the methylthioninium salt and the urolithin A are present at a weight ratio from about 1:200 to about 1:6;
the methylthioninium salt and the pyrroloquinoline quinone are present at a weight ratio from about 1:20 to about 30:1; or
a combination thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein the methylthioninium salt and the tesofensine are both present at a weight ratio from about 1:1 to about 75:1.

### Claim 5 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein the urolithin A, the pyrroloquinoline quinone, or both are present.

### Claim 6 (depends on 5)

The methylthioninium salt-containing composition of claim 5, wherein the tesofensine is present.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein a single oral dosage form includes:
about 1 mg to about 25 mg of the methylthioninium salt; and
the second mitochondria-enhancing compound is present and is selected from:
about 100 mg to about 600 mg of urolithin A,
about 0.5 mg to about 20 mg of the pyrroloquinoline quinone,
about 0.25 mg to about 2 mg of the tesofensine, or
a combination thereof.

### Claim 9 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein the composition is formulated for a daily dose based on from 1 to 4 oral dosage forms, wherein the 1 to 4 oral dosage forms include a total of from:
about 2 mg to about 50 mg of the methylthioninium salt; and
the second mitochondria-enhancing compound is present and is selected from:
about 200 mg to about 1200 mg of the urolithin A,
about 1 mg to about 40 mg of the pyrroloquinoline quinone,
about 0.5 mg to about 4 mg of the tesofensine, or
a combination thereof.

### Claim 10 (depends on 1)

The methylthioninium salt-containing composition of claim 1, further comprising nicotinamide adenine dinucleotide in the form of NADH, NAD+, or a combination thereof, wherein the composition is formulated as a single oral dosage form including from about 10 mg to about 100 mg of the nicotinamide adenine dinucleotide or wherein the composition is formulated for a daily dose based on from 1 to 4 oral dosage forms providing a total of from about 20 mg to about 200 mg of the nicotinamide adenine dinucleotide.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 10)

The methylthioninium salt-containing composition of claim 10, wherein methylthioninium salt and nicotinamide adenine dinucleotide are present at a methylthioninium salt to nicotinamide adenine dinucleotide weight ratio from about 1:100 to about 5:2, and wherein the urolithin A and nicotinamide adenine dinucleotide are present at a urolithin A to nicotinamide adenine dinucleotide weight ratio from about 1:1 to about 60:1.

### Claim 14 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein the urolithin A and the pyrroloquinoline quinone are both present at a urolithin A to pyrroloquinoline quinone weight ratio from about 5:1 to about 1200:1.

### Claim 15 (depends on 1)

The methylthioninium salt-containing composition of claim 1, wherein the methylthioninium salt is in the form of methylthioninium chloride.

### Claim 16

A method of supporting enhanced mitochondrial health in a subject, comprising orally co-administering a methylthioninium salt and a second mitochondria-enhancing compound to a subject, wherein the second mitochondria-enhancing compound is selected from urolithin A, pyrroloquinoline quinone, tesofensine, or a combination thereof, wherein orally co-administering on a daily basis is at a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4, a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1, or a combination thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein orally co-administering the methylthioninium salt and the second mitochondria-enhancing compound is via a co-formulated methylthioninium salt-containing composition.

### Claim 18 (depends on 16)

The method of claim 16, wherein orally co-administering the methylthioninium salt and the second mitochondria-enhancing compound is via a first oral dosage form containing the methylthioninium salt and a second oral dosage form containing the second mitochondria-enhancing compound.

### Claim 19 (depends on 16)

The method of claim 16, wherein the methylthioninium salt-containing composition is dosed on a daily basis with sufficient methylthioninium salt to stimulate ATP production and sufficient urolithin A to recognize or repair mitochondria damage.

### Claim 20 (depends on 16)

The method of claim 16, wherein the methylthioninium salt-containing composition is dosed on a daily basis with sufficient methylthioninium salt to stimulate ATP production and sufficient pyrroloquinoline quinone to enhance:
nicotinamide adenine dinucleotide production,
mitochondrial mitophagy,
or a combination thereof.

### Claim 21 (depends on 16)

The method of claim 16, wherein the methylthioninium salt-containing composition is dosed on a daily basis with sufficient methylthioninium salt to stimulate ATP production and sufficient tesofensine to enhance:
cognition due to increased levels of dopamine, norepinephrine, serotonin, or a combination thereof in the brain,
feelings of fullness and satisfaction by curbing appetite, or
a combination thereof.

### Claim 22 (depends on 16)

The method of claim 16, wherein orally co-administering includes orally co-administering on a daily basis:
about 2 mg to about 40 mg of the methylthioninium salt; and
the second mitochondria-enhancing compound including:
about 200 mg to about 1200 mg of the urolithin A,
about 1 mg to about 40 mg of the pyrroloquinoline quinone,
about 0.5 mg to about 4 mg of the tesofensine, or
a combination thereof.

### Claim 23 (depends on 16)

The method of claim 16, wherein orally co-administering includes orally co-administering the methylthioninium salt and the second mitochondria-enhancing compound to the subject on a daily basis for at least about one week.

### Claim 24

(canceled)

### Claim 25 (depends on 16)

The method of claim 16, wherein orally co-administering further includes orally co-administering nicotinamide adenine dinucleotide in the form of NADH, NAD+, or a combination thereof at a daily dose of from about 20 mg to about 200 mg.

### Claim at position 25

26-27. (canceled)
